What Does the Sale of Progyny Shares by the CFO Mean for Investors?
Key Points
CFO Mark Livingston sold 8,275 shares for a transaction value of ~$211,000 on May 20, 2026.
This represented 9.47% of Livingston's direct holdings, reducing his direct position to 79,063 shares.
The transaction involved only direct ownership, with no indirect or derivative securities reported.
Mark S. Livingston, Chief Financial Officer of Progyny (NASDAQ:PGNY), reported the sale of 8,275 shares of common stock in an open-market transaction on May 20, 2026, as disclosed in an SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (direct) | 8,275 |
| Transaction value | $211,000 |
| Post-transaction shares (direct) | 79,063 |
| Post-transaction value (direct ownership) | $2.03 million |
Transaction value based on SEC Form 4 reported price ($25.50); post-transaction value based on May 20, 2026 trade-date close price.
Key questions
- How meaningful was this sale as a proportion of Livingston's direct holdings?
This transaction represented 9.47% of Livingston's direct position, a moderate reduction consistent with the cadence of his prior open-market sales. - Did the sale affect indirect or derivative holdings?
No indirect or derivative holdings were reported; the activity was limited to directly held common shares, leaving Livingston with 79,063 shares post-transaction. - What does the transaction reveal about selling cadence and capacity?
Recent sales have corresponded to a decline in total available shares, with remaining direct holdings now at 43.2% of the level held in July 2023, indicating that trade size reductions are a function of reduced capacity rather than a change in selling intent.
Company overview
| Metric | Value |
|---|---|
| Revenue (TTM) | $1.29 billion |
| Net income (TTM) | $67.69 million |
| Employees | 675 |
| Price (as of market close 5/20/26) | $25.64 |
* 1-year performance metrics are calculated using May 20th, 2026 as the reference date.
Company snapshot
- Progyny offers fertility and family building benefits solutions, including differentiated plan designs, member support services, a selective network of fertility specialists, and an integrated pharmacy benefits platform.
- It operates a benefits management model, generating revenue through employer-sponsored health benefit programs and pharmacy solutions.
- The company serves employers across the United States seeking fertility and family-building benefits for their employees.
Progyny is a leading provider of fertility and family building benefits, leveraging a data-driven platform and selective provider network to deliver tailored solutions for employers. The company’s integrated approach combines plan design, member support, and pharmacy management, positioning it as a differentiated player in the healthcare benefits space.
What this transaction means for investors
The May 20 sale of Progyny stock by CFO Mark Livingston came at a time when shares were on the upswing. His disposition at $25.50 per share was close to the 52-week high of $28.75 reached in January. He subsequently sold additional shares in June.
Even so, Livingston’s sales are not a red flag for investors. They were non-discretionary transactions performed as part of a pre-arranged Rule 10b5-1 trading plan, adopted back in August of 2025. Such plans are often implemented by insiders to avoid accusations of trading based on insider information.
Progyny lost a major customer, but its shares rose in the second quarter after the company delivered strong full-year guidance for 2026. It projects revenue will increase between 6% to 9% year over year.
Excluding the sales delivered by the one large client from 2025 totals, the year-over-year revenue growth would be a whopping 10% to 13%. This suggests Progyny is seeing increased income from other customers.
Robert Izquierdo has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Progyny. The Motley Fool has a disclosure policy.